炎症性肠病中的免疫代谢和线粒体:治疗干预的作用?
Claire E Adams1, Duncan G Rutherford1, Gareth R Jones1
1Gut Research Unit, Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, UK.
Disease models & mechanisms
|October 17, 2024
概括
新型代谢疗法为炎症性肠病 (IBD) 提供了新的希望,有可能克服目前的治疗局限性. 这项研究探讨了更有效的IBD管理的代谢途径和生物标志物.
科学领域:
- 胃肠道学和免疫学
- 代谢和炎症性疾病
背景情况:
- 炎症性肠道疾病 (IBD) 是一种慢性免疫媒介的肠道疾病,原因不明,影响许多患者.
- 目前用于IBD的先进疗法,针对白细胞贩运和细胞因子信号传递,仅在50%的病例中有效.
- 线粒体功能障碍和新陈代谢在炎症中的作用在IBD病变发生过程中越来越被认可.
研究的目的:
- 为IBD治疗提供新兴代谢方法的概述.
- 挑战IBD治疗中的现有"治疗上限".
- 确定治疗干预的关键代谢途径,并重新想象IBD的代谢生物标志物.
主要方法:
- 文献综述和综合目前关于IBD代谢和炎症的研究.
- 分析证据,将线粒体功能障碍与IBD联系起来.
- 探索IBD的新代谢标和生物标志物.
主要成果:
- 越来越多的证据支持代谢失调在IBD中的作用.
- 线粒体功能障碍是IBD病理学的重要因素.
- 代谢途径为新型IBD疗法提供了有希望的目标.
结论:
- 代谢干预是IBD治疗的一个有希望的前沿,可能会比目前的治疗方法更好地改善结果.
- 识别和准特定的代谢途径可能会导致炎症性肠道疾病的更有效的治疗方法.
- 开发新的代谢生物标志物对于推进IBD管理中的个性化医学至关重要.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
323
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Drugs for Treatment of Ulcerative Colitis in IBD
126
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
126


